New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
13:25 EDTMDCO, MDCO, MDCOLeerink's biotech analysts hold an analyst/industry conference call
Biotech Analyst Schwartz, along with MEDACorp Specialist Cahrles Whitcomb, MD, discuss the prospects for The Medicines Co's Cangrelor in Percutaneous Coronary Intervention (PCI)/Acute Coronary Syndrome (ACS) on an Analyst/Industry conference call to be held on February 7 at 2 pm.
News For MDCO From The Last 14 Days
Check below for free stories on MDCO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
07:17 EDTMDCOThe Medicines Co. downgraded to Market Perform from Outperform at Leerink
Subscribe for More Information
April 4, 2014
08:43 EDTMDCOPointState Capital reports 7.3% passive stake in The Medicines Co.
Subscribe for More Information
April 3, 2014
07:05 EDTMDCOThe Medicines Co. announces FDA BLA acceptance for Fibrocaps,
The Medicines Co. announced that the U.S. Food and Drug Administration has accepted the filing of a biologic license application for the investigational hemostatic agent Fibrocaps, a dry powder formulation of fibrinogen and thrombin being developed to aid in hemostasis during surgery, where control of mild or moderate bleeding by conventional means is ineffective or impractical. The FDA action date for Fibrocaps is January 31, 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use